Literature DB >> 9449265

Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens.

B Charleston1, J J Gate, I A Aitken, B Stephan, R Froyman.   

Abstract

This study compared the efficacy of continuous or pulsed-water medication with enrofloxacin, danofloxacin, and sarafloxacin in eight groups of 90 chicks each by using an infectious bronchitis virus-Escherichia coli model of colisepticemia. The model produced lesions of typical those occurring in birds with severe colisepticemia; for the infected, nonmedicated birds the mortality was 43.5% and the morbidity was 89%, 17.8% of birds had severe lesions, and the birds had a mean air sac lesion score of 2.58. This experiment showed that continuous dosing and pulsed dosing are clinically equivalent. However, for all fluoroquinolones studied, there was a trend for the continuously mediated birds to have lower mortality and less severe disease than birds receiving pulsed doses. Compared with infected, nonmedicated controls, only birds continuously medicated with enrofloxacin had a significantly lower morbidity (32%), and only birds medicated with enrofloxacin and danofloxacin (continuous and pulsed treatments) had significantly lower mortality (6.7 and 11.0% and 16.8 and 19.2% for continuous and pulsed treatments with enrofloxacin and danofloxacin, respectively). A significantly lower proportion of birds only in the groups medicated with enrofloxacin had severe lesions (for birds receiving continuous and pulsed treatments, 2.2 and 6.7%, respectively). Birds medicated with any of the three fluoroquinolones (continuous and pulsed treatments) except pulsed-water treatment with sarafloxacin had significantly reduced mean air sac lesion scores compared with the scores for nonmedicated birds (air sac lesion scores, 0.60 and 0.83, 1.38 and 1.63, and 1.80 and 2.05 for birds receiving continuous and pulsed treatments with enrofloxacin, danofloxacin, and sarafloxacin, respectively). The performance of the birds that survived the challenge or that recovered after receiving medication was not compromised compared to the performance of noninfected birds. Enrofloxacin was more efficacious than either danofloxacin or sarafloxacin for the treatment of colisepticemia in chickens by medication in drinking water. Similarly, danofloxacin appeared to be more effective than sarafloxacin in treating colisepticemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449265      PMCID: PMC105460     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Factors affecting the development of respiratory disease complex in chickens.

Authors:  W B Gross
Journal:  Avian Dis       Date:  1990 Jul-Sep       Impact factor: 1.577

3.  Experimental reproduction of airsacculitis and septicemia by aerosol exposure of 1-day-old chicks using Congo red-positive Escherichia coli.

Authors:  K M Gjessing; H A Berkhoff
Journal:  Avian Dis       Date:  1989 Jul-Sep       Impact factor: 1.577

4.  The experimental infection of chickens with mixtures of infectious bronchitis virus and Escherichia coli.

Authors:  H W Smith; J K Cook; Z E Parsell
Journal:  J Gen Virol       Date:  1985-04       Impact factor: 3.891

5.  Genetic differences in susceptibility to a mixture of avian infectious bronchitis virus and Escherichia coli.

Authors:  N Bumstead; M B Huggins; J K Cook
Journal:  Br Poult Sci       Date:  1989-03       Impact factor: 2.095

6.  Pathogenicity of Escherichia coli in aerosols for young chickens.

Authors:  H W Yoder; C W Beard; B W Mitchell
Journal:  Avian Dis       Date:  1989 Oct-Dec       Impact factor: 1.577

7.  Escherichia coli challenge in chickens selected for high or low antibody response and differing in haplotypes at the major histocompatibility complex.

Authors:  E A Dunnington; P B Siegel; W B Gross
Journal:  Avian Dis       Date:  1991 Oct-Dec       Impact factor: 1.577

8.  In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials.

Authors:  D L Raemdonck; A C Tanner; S T Tolling; S L Michener
Journal:  Avian Dis       Date:  1992 Oct-Dec       Impact factor: 1.577

9.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Bacterial colonization and in vivo expression of F1 (type 1) fimbrial antigens in chickens experimentally infected with pathogenic Escherichia coli.

Authors:  C M Dozois; N Chanteloup; M Dho-Moulin; A Brée; C Desautels; J M Fairbrother
Journal:  Avian Dis       Date:  1994 Apr-Jun       Impact factor: 1.577

View more
  7 in total

1.  Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Authors:  Aneliya Milanova Haritova; Nikolina Velizarova Rusenova; Parvan Rusenov Parvanov; Lubomir Dimitrov Lashev; Johanna Fink-Gremmels
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Modification of enrofloxacin treatment regimens for poultry experimentally infected with Salmonella enterica serovar Typhimurium DT104 to minimize selection of resistance.

Authors:  Luke P Randall; Sue W Cooles; Nick C Coldham; Ken S Stapleton; Laura J V Piddock; Martin J Woodward
Journal:  Antimicrob Agents Chemother       Date:  2006-10-09       Impact factor: 5.191

3.  Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys.

Authors:  A M Haritova; N V Rusenova; P R Parvanov; L D Lashev; J Fink-Gremmels
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

4.  Bacterial ghost of avian pathogenic E. coli (APEC) serotype O78:K80 as a homologous vaccine against avian colibacillosis.

Authors:  Hakimeh Ebrahimi-Nik; Mohammad Reza Bassami; Mehrdad Mohri; Mehrnaz Rad; Mazhar I Khan
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

5.  Design, development, and evaluation of the efficacy of a nucleic acid-free version of a bacterial ghost candidate vaccine against avian pathogenic E. coli (APEC) O78:K80 serotype.

Authors:  Safoura Soleymani; Amin Tavassoli; Gholamreza Hashemi Tabar; Gholam Ali Kalidari; Hesam Dehghani
Journal:  Vet Res       Date:  2020-12-09       Impact factor: 3.683

6.  Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers.

Authors:  Mengjie Guo; Shamsuddin Bughio; Yong Sun; Yu Zhang; Lingling Dong; Xiaohua Dai; Liping Wang
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

7.  Analysis of immune responses induced by avian pathogenic Escherichia coli infection in turkeys and their association with resistance to homologous re-challenge.

Authors:  Jean-Rémy Sadeyen; Pete Kaiser; Mark P Stevens; Francis Dziva
Journal:  Vet Res       Date:  2014-02-14       Impact factor: 3.683

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.